4月1日 - ** 制药商Axsome Therapeutics AXSM.O股价上涨1.5%至171.48美元
** 该公司称已从日本武田公司获得治疗精神分裂症和抽动秽语综合征的实验性口服药物balipodect的全球使用权
** Balipodect 以一种特定的脑酶为靶点，以前被称为 TAK-063；已在 164 名患者中进行了精神分裂症中期研究测试 - AXSM
** 该公司称，该药物在360多人的研究中显示出良好的安全性
** Axsome 计划今年晚些时候开始准备晚期精神分裂症试验 - AXSM
** 武田将获得预付款、潜在的开发和销售里程碑以及未来销售的版税 - AXSM
** 截至上次收盘，AXSM 年度跌幅约为 7%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.